InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,870.62
(
-1.32%
)
US TECH 100
19,880.00
(
-2.30%
)
Dow Jones
43,444.99
(
-0.70%
)
Brent Oil
71.25
(
0.00%
)
Bitcoin
89,308.36
(
-1.41%
)
Post# of 253650
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120737
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Tuesday, 03/04/2008 7:26:42 PM

Tuesday, March 04, 2008 7:26:42 PM

Post# of 253650
IDIX 2008-2009 Clinical Goals

[Updated based on guidance
from Susquehanna webcast.]


HIV

Mid 2008: Complete phase-1/2 IDX899 7-day monotherapy study using lower doses than 800mg. (Data from the 800mg cohort were reported on 2/6/08: #msg-26606685.) Report results at a medical conference in June.

3Q08: Start phase-2 IDX899 6-week combination study, IDX899+Truvada vs Sustiva+Truvada in first- and second-line patients.

End 2008: Partner IDX899 program following above phase-2 study.


HCV

April 2008: Report preclinical data on IDX184 at EASL (#msg-27106080).

Mid 2008: File IND/CTA for IDX184.

End 2008: Report initial human data for IDX184.

1H09: File IND/CTA for HCV protease inhibitor.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up